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benefits are gradually lost and graft function deterio-
rates, resulting in recurrence of clinical symptoms.3-5
The poor performance of the SV in comparison to the
ITA when used as a bypass conduit is widely known.3-5
Although early occlusions of the SV are thought to be
chiefly caused by intimal hyperplasia, the mechanism
of vascular proliferation remained unclear.
Angiotensin II plays an important role in vascular
proliferation through the induction of growth factors
and extracellular matrix, both of which participate in
the first stages of the repair process.6-8 Borland and
colleagues9 reported that the contractile response of
angiotensin II in isolated human SVs was greater than
that in ITAs, suggesting that the SV exhibits greater
angiotensin II–mediated action than the ITA. In graft
C oronary artery bypass grafting has offered patientswith ischemic heart disease a significant improve-
ment in longevity.1,2 The internal thoracic artery (ITA)
and the saphenous vein (SV) are frequently used as
coronary artery bypass conduits. However, the clinical
Objectives: The great saphenous vein graft is known to be less patent than the
internal thoracic artery graft. Recently, we reported that chymase-dependent
angiotensin II formation plays an important role in the development of inti-
mal hyperplasia in dog grafted veins. In this study we investigated the levels
of angiotensin II–forming enzymes, angiotensin-converting enzyme, and
chymase in human saphenous veins and internal thoracic arteries.
Methods: The saphenous vein and internal thoracic artery specimens were
obtained from coronary artery bypass grafts of patients during surgical pro-
cedures (saphenous vein, n = 16; internal thoracic artery, n = 16). Activities
of angiotensin-converting enzyme and chymase were determined by using
the extract from the saphenous vein or internal thoracic artery. Sections of
the saphenous vein or internal thoracic artery were stained with van Gieson’s
elastin stain and were immunostained with anti-human chymase antibody.
Results: The activities of angiotensin-converting enzyme in the saphenous
vein and internal thoracic artery were 0.34 ± 0.12 and 0.32 ± 0.17 mU/mg
protein, respectively, and the difference was not significant. The chymase
activity in the saphenous vein was significantly higher than that in the inter-
nal thoracic artery (saphenous vein, 10.1 ± 0.81 mU/mg protein; internal tho-
racic artery, 6.21 ± 1.86 mU/mg protein). Chymase-positive cells in the
saphenous vein were located in both the media and adventitia, and those in
the internal thoracic artery were located only in the adventitia. The number
of chymase-positive cells in the saphenous vein was about 2.6 times that in
the internal thoracic artery.
Conclusion: The chymase activity, but not the angiotensin-converting
enzyme activity, was significantly higher in the saphenous vein, suggesting
that the high levels of chymase activity may be related to the poorer perfor-
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experimental models an angiotensin-converting enzyme
(ACE) inhibitor was effective in preventing vascular
proliferation in rats, whereas it was not effective in
baboons.10,11 Such species differences in the effects of
ACE inhibitors on neointimal formation may depend
on species differences in the angiotensin II–forming
pathways. Rat vascular tissues contain ACE as the
only angiotensin II–forming enzyme, whereas vascu-
lar tissues of humans, monkeys, dogs, and hamsters
contain chymase in addition to ACE as angiotensin
II–forming enzymes.12-15 Therefore, it is thought that
ACE inhibitors could not suppress chymase-depen-
dent angiotensin II formation, resulting in vascular
proliferation in primate vessels, despite the prevention
of such proliferation in rats. Recently, we demonstrat-
ed that a chymase inhibitor prevents vascular prolifer-
ation in dog grafted veins.16 This finding suggests that
the chymase may play an important role in the devel-
opment of vascular proliferation in grafted veins.
In the present study we investigated the levels of the
angiotensin II–forming enzymes, ACE and chymase, and
the distribution of chymase-positive cells in human SVs
and ITAs.
Methods
Human vessels. ITA and SV specimens were obtained
from 16 patients who underwent coronary artery bypass
surgery (14 men and 2 women; age range, 48-80 years). No
patients received ACE-inhibition therapy before their opera-
tions. All subjects gave written consent after a full explana-
tion of the purpose of this study. The protocol of this study
complied with the principles of the Helsinki Declaration.
Preparation of vascular tissue. The ITA or SV specimens
were minced and homogenized in 10 volumes (wt/vol) of 20
mmol/L Na-phosphate buffer (pH 7.4). The homogenate was
centrifuged at 20,000g for 30 minutes. The supernatant was
discarded, and the pellet was resuspended and homogenized
in 5 volumes (wt/vol) of 10 mmol/L Na-phosphate buffer (pH
7.4), containing 2 mol/L KCl and 0.1% Nonidet P-40. The
homogenate was stored overnight at 4°C and centrifuged at
20,000g for 30 minutes. The supernatant was used for mea-
surement of the ACE and chymase activities.
Measurement of enzyme activities. The ACE activity was
measured with a synthetic substrate, hippuryl-His-Leu,
specifically designed for ACE (Peptide Institute Inc, Osaka,
Japan). Fifty microliters of tissue extract or plasma was incu-
bated for 30 minutes at 37°C with 5 mmol/L hippuryl-His-
Leu in 250 µL of 10 mmol/L phosphate buffer (pH 8.3), con-
taining 600 mmol/L NaCl.17,18 The reaction was terminated
by addition of 750 µL of 3% metaphosphoric acid, and then
the mixture was centrifuged at 20,000g for 5 minutes at 4°C.
The supernatant was applied to a reversed-phase column (4
mm intradermally × 250 mm; IRICA Instrument, Kyoto,
Japan), which had been equilibrated with 10 mmol/L
KH2PO4 and CH3OH (1:1, pH 3.0) and eluted with the same
solution at a rate of 0.3 mL/min.17,18 Hippuric acid was
detected by using ultraviolet absorbance at 228 nm. One unit
of ACE activity was defined as the amount of enzyme that
cleaved 1 µmol/L of hippuric acid per minute.
The chymase activity was measured by incubating tissue
extracts for 30 minutes at 37°C with 770 µmol/L
angiotensin I in 150 mmol/L borax-borate buffer (pH 8.5),
containing 8 mmol/L dipyridyl, 770 µmol/L di-isopropyl
fluorophosphate, and 5 mmol/L ethylenediamine tetraacetic
acid, as described previously.12,18 The reaction was termi-
nated by addition of 15% trichloroacetic acid, and then the
mixture was centrifuged at 20,000g for 5 minutes at 4°C.
For fluorometric quantitation of His-Leu formed from an
angiotensin I substrate, 10% o-phthaldialdehyde (dissolved
in methanol) was added to the supernatant in the alkaline
state and was incubated for 10 minutes at room temperature.
Reaction was terminated by addition of 6 mol/L HCl, and
the fluorescence was measured at 340 nm excitation and
455 nm emission. One unit of chymase activity was defined
as the amount of enzyme that cleaved 1 µmol of His-Leu per
minute. A blank was also included (ie, the addition of 500
mmol/L chymostatin).
The total angiotensin II–forming activity was measured
by incubating tissue extracts for 30 minutes at 37°C with 1
mmol/L angiotensin I in 20 mmol/L Tris-HCl buffer con-
taining 0.1% Triton X-100 (pH 8.5). The reaction was ter-
minated by addition of 15% trichloroacetic acid, and then
the mixture was centrifuged at 20,000g for 5 minutes at
4°C. The supernatant was applied to a reversed-phase col-
umn (ODS 80-Tm, 4.6 mm intradermally × 250 mm;
Tohso, Yamaguchi, Japan), which had been equilibrated
with 30% CH3OH in 10 mmol/L phosphoric acid and elut-
ed with a linear gradient of 30% to 90% CH3OH in 10
mmol/L phosphoric acid at a rate of 1 mL/min. The
angiotensin II concentration was detected by using ultra-
violet absorbance at 226 nm and was determined as the
quantity of angiotensin II formed per minute.19
Protein concentration was assayed with BCA Protein
Assay Reagents (Pierce, Rockford, Ill) by using bovine
serum albumin as a standard.
Histologic analysis. The ITA or SV segments were fixed in
10% methanol-Carnoy fixative overnight and embedded in
paraffin. The sections were cut from each block at 3-µm thick-
ness. The sections were stained with hematoxylin-eosin and van
Gieson elastin stain, respectively.
The other sections were used for immunohistochemical
staining. The primary antibody for anti-human chymase used
in the present study was the following: mouse anti-human
chymase monoclonal immunoglobulin G (1:1000 dilution;
Chemicon International Inc, Temecula, Calif). Immuno-
histochemical staining was performed with an avidin-biotin-
peroxidase kit (Dako LSAB kit; DAKO Corporation,
Carpinteria, Calif) with 3-amino-9-ethylcarbazole color
development. As a negative control, the primary antibody was
omitted and replaced by an equal concentration of nonim-
mune mouse monoclonal immunoglobulin G.
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The number of chymase-positive cells was quantified
with an image-analysis system (VM-30; Olympus Optical
Co, Tokyo, Japan).
Statistical analysis. All data shown in the text were
expressed as means ± SD. Data were analyzed by using the
2-tailed Student t test for paired observations.
Results
Enzyme activities in ITA and SV. The ACE activity
in the ITA was 0.32 ± 0.68 mU/mg protein, whereas
that in the SV was 0.34 ± 0.48 mU/mg protein, and this
difference was not significant. The chymase activity in
the ITA was 6.21 ± 7.44 mU/mg protein, whereas that
in the SV was 10.1 ± 3.24 mU/mg protein, and this dif-
ference was significant (P = .045). When the activity of
each enzyme in the ITA was regarded as 100%, the
ACE and chymase activities in the SV were 106.3%
and 162.6%, respectively (Fig 1, A and B). The total
angiotensin II–forming activity was also increased in
the SV compared with the ITA (ITA, 4.57 ± 3.28
mU/mg protein; SV, 7.47 ± 4.16 mU/mg protein), and
the ratio of the SV to the ITA was 163.5% (Fig 1, C).
This difference was also significant (P = .01).
Histochemical study in SV and ITA. Immuno-
staining with an antibody to human chymase localizes
this enzyme to the medial and adventitial layers in the
SV, whereas in the ITA immunostaining reveals the
enzyme only in the adventitial layer (Fig 2). The num-
ber of chymase-positive cells in the SV was 8.80 ± 1.72
cells/mm2, whereas that in the ITA was 3.36 ± 3.23
cells/mm2 (Fig 3), and this difference was significant
(P = .0001).
Discussion
In this study we demonstrated that the chymase activ-
ity, but not the ACE activity, was significantly higher in
the SV than in the ITA. The ratio of chymase activity in
the SV to that in the ITA was 162.6%, and the total
angiotensin II–forming activity was 163.5% in the SV.
This high level of total angiotensin II–forming activity
in the SV is thought to be dependent on the upregulat-
ed chymase activity. The number of chymase-positive
cells in the SV was significantly higher than in the ITA.
In particular, the chymase-positive cells were observed
in the medial layer only in the SV. In general, chymase
is widely known to be contained only in mast cells,20,21
and the chymase-positive cells were also identified as
the mast cells in this study (data not shown). Therefore
the number of chymase-positive mast cells in the SV
was higher than that in the ITA, resulting in the high
level of angiotensin II–forming activity by the upregu-
lated chymase activity in the SV.
Previously, Borland and colleagues9 reported that the
angiotensin II–induced vascular contraction in isolated
human SV was greater than that in the ITA and that the
responses were mediated through the angiotensin type
1 (AT1) receptor but not through the AT2 receptor. The
greater action of angiotensin II through the AT1 recep-
tor in the SV may potentiate the development of vascu-
lar hyperplasia. On the other hand, it has been reported
that ITA and SV contain chymase as an angiotensin
II–forming enzyme.22,23 However, the levels of ACE
and chymase in the SV or ITA remained unclear. In this
study we demonstrated for the first time that the
angiotensin II–forming activity by chymase, but not by
The Journal of Thoracic and
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Fig 1. ACE (A), chymase (B), and total angiotensin II–forming activities (C) in the ITA (open column) and SV
(closed column). Activity of each enzyme in the ITA was regarded as 100%. *P < .05 versus ITA.
A B C
ACE, was increased in the SV compared with the ITA.
The high level of angiotensin II–forming activity
caused by chymase, in addition to the activated
angiotensin II–induced response, may play a crucial
role in vascular hyperplasia.
In the dog graft model we reported that ACE and chy-
mase activities in the grafted veins were significantly
increased 2- and 15-fold, respectively, compared with
untreated veins 28 days after the grafting.19 The ACE
and chymase activities in the grafted veins were acti-
vated after grafting, and angiotensin II–forming activi-
ty through chymase was especially accelerated, sug-
gesting that the activated angiotensin II formation by
means of chymase may be important in the develop-
ment of vascular proliferation. In fact, in this model the
vascular proliferation was suppressed by a chymase
inhibitor.19 It is reported that chymase, an enzyme that
is present in mast cell granules, is released from the
granules on strong stimulation, such as in injured ves-
sels after grafting, and then mast cells accumulate.20,21
Although chymase is known to activate angiotensin I to
angiotensin II, it also activates stem cell factor, a typi-
cal cytokine that has the ability to induce accumulation
of mast cells. In this study the level of chymase in the
SV was higher than that in the ITA. After grafting, the
high number of chymase-positive mast cells in the SV
may easily induce the additional accumulation of mast
cells through the activation of stem cell factor by chy-
mase. In fact, in a dog model the number of mast cells
and chymase activity were increased in the grafted
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Fig 2. Sections (3 µm each) from the ITA (A) and SV (B) were stained with van Gieson elastin stain. For immuno-
histochemical analysis, sections (3 µm each) from the ITA (C) and SV (D) were performed with an antibody for
human chymase and were performed by using an avidin-biotin-peroxidase kit with 3-amino-9-ethylcarbazole color
development. (Original magnification, 35×.)
veins, whereas chymase inhibitor suppressed not only
chymase activity but also the number of mast cells.19
Moreover, the chymase-positive mast cells were
observed in the medial layer only in the SV. Cytokines
activated by chymase in the medial layer, such as stem
cell factor, which is filled with smooth muscle cells
(SMCs), may induce an increase in chymase-positive
mast cells in the SMCs. The proliferation of SMCs is
an important component of vascular hyperplasia, and
angiotensin II plays a key role in regulating the growth
of vascular SMCs.24 The increase of chymase-depen-
dent angiotensin II formation in the medial layer of the
SV may be involved in the growth of SMCs.
In a clinical study restenosis after percutaneous trans-
luminal coronary angioplasty was prevented by a
degranulating inhibitor for mast cells, tranilast.25
Although tranilast has been widely used for the clinical
treatment of bronchial asthma and atopic dermati-
tis,26,27 its mechanism of preventive effect in restenosis
after percutaneous transluminal coronary angioplasty
has been unclear. Recently, we demonstrated that trani-
last prevented vascular hyperplasia in a balloon injury
dog model.28 In this model both the number of mast
cells and chymase activity were increased in the vessels
injured by a balloon catheter 30 days after the injury,
whereas the treatment of tranilast inhibited not only the
accumulation of mast cells but also the increased chy-
mase activity. These findings suggest that accumula-
tion of chymase-positive mast cells is closely related to
vascular hyperplasia.
In later occlusion, intimal hyperplasia after coronary
artery bypass grafting may be due to the development of
atherosclerosis. Previously, we demonstrated that chy-
mase, ACE, and angiotensin II concentration were signif-
icantly increased in the atherosclerotic lesions in mon-
keys fed a high-cholesterol diet.29,30 In this model
angiotensin II receptor antagonist significantly sup-
pressed the atherosclerotic area.29 These findings suggest
that increased angiotensin II levels play an important role
in the development of atherosclerosis. In this study the
angiotensin II–forming activity was increased in the SV,
and the high levels of angiotensin II–forming ability in
the SV may also induce the intimal hyperplasia.
In conclusion, we demonstrated that angiotensin
II–forming activity through chymase in the SV was
higher than that in the ITA, and the chymase-positive
mast cells in the medial layer may play an important
role in the development of vascular hyperplasia in the
SV used as a graft conduit.
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